Dr Volpe graduated from Duke University in 2008 with PhD in computational biology and bioinformatics, with a concentration in immunology. His research involved developing a software algorithm to decipher the germline origins of human immunoglobulin and T-cell receptors and then using that software to analyze large data sets of human antibodies to understand their diversity. He received the American Association of Immunologists-Huang Foundation Young Investigator Award in 2007 for his work in anti-HIV antibody composition.

Dr Klein is board certified in anatomic and clinical pathology, hematopathology and molecular genetic pathology.  He earned his medical degree from Sackler School of Medicine, New York State program, Tel Aviv, Israel. He completed his residency in Anatomic and Clinical Pathology at Winthrop University Hospital, Mineola NY, where he served as chief resident and performed his fellowship training in Hematopathology and Molecular Genetic Pathology at Washington University – Barnes Jewish Hospital, St.

Dr Kearney received his PhD in genetics and molecular biology from the University of North Carolina at Chapel Hill in 2003, where he studied vascular development and tumor neovascularization. During a subsequent post-doctoral fellowship in neurogenetics, Dr Kearney developed a research interest in the genetics of neurodevelopmental disorders. He received his clinical molecular genetics training at the Greenwood Genetic Center and the Fullerton Genetics Center, where his studies focused on developing new genetic tests for the diagnosis of Autism Spectrum Disorders.

Dr Collins is a fellow of the American Board of Forensic Toxicology and holds certification as a high-complexity laboratory director (HCLD) from the American Board of Bioanalysis. She earned her PhD from Northwestern University and a Public Health Certificate in Core Concepts (PHCert-CC) from the University of Minnesota. She is currently a laboratory director at MedTox Laboratories, a member of the Labcorp Specialty Testing Group. She joined MedTox in 1994.

Dr. Otvos received a Ph.D. in comparative biochemistry from the University of California-Berkeley and postdoctoral training in molecular biophysics at Yale University.  He spent the following 20 years in academia, first on the chemistry faculty of the University of Wisconsin-Milwaukee and then as Professor of Biochemistry at North Carolina State University during which time he developed new technology for measuring lipoprotein particles using nuclear magnetic resonance (NMR) spectroscopy. He then founded LipoScience, Inc.